Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F: Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology 2020, 159(1):335–349.e315.

Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell 2012, 150(1):12–27.

Mattei AL, Bailly N, Meissner A: DNA methylation: a historical perspective. Trends in Genetics : TIG 2022, 38(7):676–707.

Pan Y, Ma P, Liu Y, Li W, Shu Y: Multiple functions of m(6)A RNA methylation in cancer. Journal of Hematology & Oncology 2018, 11(1):48.

Yano S, Ishiuchi T, Abe S, Namekawa SH, Huang G, Ogawa Y, Sasaki H: Histone H3K36me2 and H3K36me3 form a chromatin platform essential for DNMT3A-dependent DNA methylation in mouse oocytes. Nature Communications 2022, 13(1):4440.

Li J, Yuan S, Norgard RJ, Yan F, Sun YH, Kim IK, Merrell AJ, Sela Y, Jiang Y, Bhanu NV et al: Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Cancer Discovery 2021, 11(3):736–753.

Uddin MS, Mamun AA, Alghamdi BS, Tewari D, Jeandet P, Sarwar MS, Ashraf GM: Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches. Seminars in Cancer Biology 2022, 83:100–120.

Mercer TR, Dinger ME, Mattick JS: Long non-coding RNAs: insights into functions. Nature Reviews Genetics 2009, 10(3):155–159.

Cao J, Yan Q: Cancer Epigenetics, Tumor Immunity, and Immunotherapy. Trends in Cancer 2020, 6(7):580–592.

Wimalasena VK, Wang T, Sigua LH, Durbin AD, Qi J: Using Chemical Epigenetics to Target Cancer. Molecular Cell 2020, 78(6):1086–1095.

Lin YT, Wu KJ: Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-β signaling. Journal of Biomedical Science 2020, 27(1):39.

Li S, Kuo HD, Yin R, Wu R, Liu X, Wang L, Hudlikar R, Peter RM, Kong AN: Epigenetics/epigenomics of triterpenoids in cancer prevention and in health. Biochemical Pharmacology 2020, 175:113890.

Delaunay S, Frye M: RNA modifications regulating cell fate in cancer. Nature Cell Biology 2019, 21(5):552–559.

Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C: YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell research 2017, 27(3):315–328.

Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M et al: Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 2012, 485(7397):201–206.

He PC, He C: m(6) A RNA methylation: from mechanisms to therapeutic potential. The EMBO Journal 2021, 40(3):e105977.

Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, Hershkovitz V, Peer E, Mor N, Manor YS et al: Stem cells. m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation. Science (New York, NY) 2015, 347(6225):1002–1006.

Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, Bailis W, Cao G, Kroehling L, Chen Y et al: m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature 2017, 548(7667):338–342.

Kane SE, Beemon K: Precise localization of m6A in Rous sarcoma virus RNA reveals clustering of methylation sites: implications for RNA processing. Molecular and Cellular Biology 1985, 5(9):2298–2306.

Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR: Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell 2012, 149(7):1635–1646.

Meyer KD, Jaffrey SR: Rethinking m(6)A Readers, Writers, and Erasers. Annual Review of Cell and Developmental Biology 2017, 33:319–342.

Chen XY, Zhang J, Zhu JS: The role of m(6)A RNA methylation in human cancer. Molecular Cancer 2019, 18(1):103.

Guo T, Duan H, Chen J, Liu J, Othmane B, Hu J, Li H, Zu X: N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology 2021, 11:718644.

Lan Q, Liu PY, Haase J, Bell JL, Hüttelmaier S, Liu T: The Critical Role of RNA m(6)A Methylation in Cancer. Cancer Research 2019, 79(7):1285–1292.

Wang P, Doxtader KA, Nam Y: Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases. Molecular Cell 2016, 63(2):306–317.

Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS et al: Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Research 2014, 24(2):177–189.

Wen J, Lv R, Ma H, Shen H, He C, Wang J, Jiao F, Liu H, Yang P, Tan L et al: Zc3h13 Regulates Nuclear RNA m(6)A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Molecular Cell 2018, 69(6):1028–1038.e1026.

Knuckles P, Lence T, Haussmann IU, Jacob D, Kreim N, Carl SH, Masiello I, Hares T, Villaseñor R, Hess D et al: Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes & development 2018, 32(5–6):415–429.

Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z, Cheng T, Gao M, Shu X, Ma H et al: VIRMA mediates preferential m(6)A mRNA methylation in 3’UTR and near stop codon and associates with alternative polyadenylation. Cell Discovery 2018, 4:10.

Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, Tu BP, Conrad NK: The U6 snRNA m(6)A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention. Cell 2017, 169(5):824–835.e814.

Wang Y, Zhang L, Ren H, Ma L, Guo J, Mao D, Lu Z, Lu L, Yan D: Role of Hakai in m(6)A modification pathway in Drosophila. Nature Communications 2021, 12(1):2159.

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG et al: N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nature Chemical Biology 2011, 7(12):885–887.

Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vågbø CB, Shi Y, Wang WL, Song SH et al: ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Molecular Cell 2013, 49(1):18–29.

Wang T, Kong S, Tao M, Ju S: The potential role of RNA N6-methyladenosine in Cancer progression. Molecular Cancer 2020, 19(1):88.

Wu R, Liu Y, Yao Y, Zhao Y, Bi Z, Jiang Q, Liu Q, Cai M, Wang F, Wang Y et al: FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochimica ET Biophysica Acta-molecular And Cell Biology Of Lipids 2018, 1863(10):1323–1330.

Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C et al: R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell 2018, 172(1–2):90–105.e123.

Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, Hao YJ, Ping XL, Chen YS, Wang WJ et al: FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Research 2014, 24(12):1403–1419.

Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C et al: m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nature Communications 2019, 10(1):2782.

Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G et al: N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 2014, 505(7481):117–120.

Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J, Wu L: YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nature Communications 2016, 7:12626.

Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY et al: Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Molecular Cell 2016, 61(4):507–519.

Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y, Sha J, Huang X, Guerrero L, Xie P et al: YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. eLife 2017, 6.

Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, Qi M, Lu Z, Shi H, Wang J et al: Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Research 2017, 27(9):1115–1127.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL et al: Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nature Cell Biology 2018, 20(3):285–295.

Zhao BS, Roundtree IA, He C: Post-transcriptional gene regulation by mRNA modifications. Nature Reviews Molecular Cell Biology 2017, 18(1):31–42.

Alarcón CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF: HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events. Cell 2015, 162(6):1299–1308.

Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T: N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 2015, 518(7540):560–564.

Aik W, Scotti JS, Choi H, Gong L, Demetriades M, Schofield CJ, McDonough MA: Structure of human RNA N⁶-methyladenine demethylase ALKBH5 provides insights into its mechanisms of nucleic acid recognition and demethylation. Nucleic Acids Research 2014, 42(7):4741–4754.

Feng C, Liu Y, Wang G, Deng Z, Zhang Q, Wu W, Tong Y, Cheng C, Chen Z: Crystal structures of the human RNA demethylase Alkbh5 reveal basis for substrate recognition. The Journal of Biological Chemistry 2014, 289(17):11571–11583.

Tang C, Klukovich R, Peng H, Wang Z, Yu T, Zhang Y, Zheng H, Klungland A, Yan W: ALKBH5-dependent m6A demethylation controls splicing and stability of long 3’-UTR mRNAs in male germ cells. Proceedings of the National Academy of Sciences of the United States of America 2018, 115(2):E325-e333.

Thalhammer A, Bencokova Z, Poole R, Loenarz C, Adam J, O’Flaherty L, Schödel J, Mole D, Giaslakiotis K, Schofield CJ et al: Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor 1α (HIF-1α). PloS One 2011, 6(1):e16210.

Wang HF, Kuang MJ, Han SJ, Wang AB, Qiu J, Wang F, Tan BY, Wang DC: BMP2 Modified by the m(6)A Demethylation Enzyme ALKBH5 in the Ossification of the Ligamentum Flavum Through the AKT Signaling Pathway. Calcified Tissue International 2020, 106(5):486–493.

Yu J, Shen L, Liu Y, Ming H, Zhu X, Chu M, Lin J: The m6A methyltransferase METTL3 cooperates with demethylase ALKBH5 to regulate osteogenic differentiation through NF-κB signaling. Molecular and Cellular Biochemistry 2020, 463(1–2):203–210.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians 2021, 71(3):209–249.

Yang P, Wang Q, Liu A, Zhu J, Feng J: ALKBH5 Holds Prognostic Values and Inhibits the Metastasis of Colon Cancer. Pathology Oncology Research : POR 2020, 26(3):1615–1623.

Yan G, An Y, Xu B, Wang N, Sun X, Sun M: Potential Impact of ALKBH5 and YTHDF1 on Tumor Immunity in Colon Adenocarcinoma. Frontiers in Oncology 2021, 11:670490.

Zhai J, Chen H, Wong CC, Peng Y, Gou H, Zhang J, Pan Y, Chen D, Lin Y, Wang S et al: ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy. Gastroenterology 2023, 165(2):445–462.

Ge J, Liu SL, Zheng JX, Shi Y, Shao Y, Duan YJ, Huang R, Yang LJ, Yang T: RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8(+) T cell infiltration in colorectal cancer. Translational Oncology 2023, 34:101683.

Zhang Z, Wang L, Zhao L, Wang Q, Yang C, Zhang M, Wang B, Jiang K, Ye Y, Wang S et al: N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation. Clinical and Translational Medicine 2022, 12(8):e940.

Wu S, Yun J, Tang W, Familiari G, Relucenti M, Wu J, Li X, Chen H, Chen R: Therapeutic m(6)A Eraser ALKBH5 mRNA-Loaded Exosome-Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models. ACS Nano 2023, 17(12):11838–11854.

Shen D, Lin J, Xie Y, Zhuang Z, Xu G, Peng S, Tang G, Bai L, Zhu M, Zhang Y et al: RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner. Clinical and Translational Medicine 2023, 13(5):e1279.

Guo T, Liu DF, Peng SH, Xu AM: ALKBH5 promotes colon cancer progression by decreasing methylation of the lncRNA NEAT1. American Journal Of Translational Research 2020, 12(8):4542–4549.

Wu X, Dai M, Li J, Cai J, Zuo Z, Ni S, Zhang Q, Zhou Z: m(6)A demethylase ALKBH5 inhibits cell proliferation and the metastasis of colorectal cancer by regulating the FOXO3/miR-21/SPRY2 axis. American Journal Of Translational Research 2021, 13(10):11209–11222.

Shao Y, Liu Z, Song X, Sun R, Zhou Y, Zhang D, Sun H, Huang J, Wu C, Gu W et al: ALKBH5/YTHDF2-mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation. Clinical and Translational Medicine 2023, 13(7):e1318.

Luo J, Yu H, Yuan Z, Ye T, Hu B: ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells. Clinical & translational Oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2023, 25(7):2265–2276.

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS: Hepatocellular carcinoma. Nature Reviews Disease Primers 2021, 7(1):6.

You Y, Wen D, Zeng L, Lu J, Xiao X, Chen Y, Song H, Liu Z: ALKBH5/MAP3K8 axis regulates PD-L1 + macrophage infiltration and promotes hepatocellular carcinoma progression. International Journal of Biological Sciences 2022, 18(13):5001–5018.

Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, Shen S, Jeong S, Li Z, Zhu Y et al: M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. Cancer Research 2021, 81(18):4778–4793.

Yang Q, Liang Y, Shi Y, Shang J, Huang X: The ALKBH5/SOX4 axis promotes liver cancer stem cell properties via activating the SHH signaling pathway. Journal of Cancer Research and Clinical Oncology 2023, 149(17):15499–15510.

Han S, Xue L, Wei Y, Yong T, Jia W, Qi Y, Luo Y, Liang J, Wen J, Bie N et al: Bone Lesion-Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5-Targeting miR-3190-5p. Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 2023, 10(17):e2207080.

Zhang H, Liu Y, Wang W, Liu F, Wang W, Su C, Zhu H, Liao Z, Zhang B, Chen X: ALKBH5-mediated m(6)A modification of lincRNA LINC02551 enhances the stability of DDX24 to promote hepatocellular carcinoma growth and metastasis. Cell Death & Disease 2022, 13(11):926.

Wang W, Huang Q, Liao Z, Zhang H, Liu Y, Liu F, Chen X, Zhang B, Chen Y, Zhu P: ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner. Experimental Hematology & Oncology 2023, 12(1):1.

Chen Y, Zhao Y, Chen J, Peng C, Zhang Y, Tong R, Cheng Q, Yang B, Feng X, Lu Y et al: ALKBH5 suppresses malignancy of hepatocellular carcinoma via m(6)A-guided epigenetic inhibition of LYPD1. Molecular Cancer 2020, 19(1):123.

Chen Y, Zhou P, Deng Y, Cai X, Sun M, Sun Y, Wu D: ALKBH5-mediated m(6) A demethylation of TIRAP mRNA promotes radiation-induced liver fibrosis and decreases radiosensitivity of hepatocellular carcinoma. Clinical and Translational Medicine 2023, 13(2):e1198.

Kamisawa T, Wood LD, Itoi T, Takaori K: Pancreatic cancer. Lancet (London, England) 2016, 388(10039):73–85.

Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang Y, Feng Y, Pan Q, Wan R: RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Molecular Cancer 2020, 19(1):91.

He Y, Hu H, Wang Y, Yuan H, Lu Z, Wu P, Liu D, Tian L, Yin J, Jiang K et al: ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation. Cellular Physiology and Biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018, 48(2):838–846.

He Y, Yue H, Cheng Y, Ding Z, Xu Z, Lv C, Wang Z, Wang J, Yin C, Hao H et al: ALKBH5-mediated m(6)A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death & Disease 2021, 12(12):1121.

Huang R, Yang L, Zhang Z, Liu X, Fei Y, Tong WM, Niu Y, Liang Z: RNA m(6)A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism. Frontiers in Cell and Developmental Biology 2021, 9:724282.

Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, He S, Shimamoto F: m(6)A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Molecular Cancer 2020, 19(1):3.

Zhang Y, Liu X, Wang Y, Lai S, Wang Z, Yang Y, Liu W, Wang H, Tang B: The m(6)A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway. Molecular Cancer 2022, 21(1):174.

Liu X, Feng M, Hao X, Gao Z, Wu Z, Wang Y, Du L, Wang C: m6A methylation regulates hypoxia-induced pancreatic cancer glycolytic metabolism through ALKBH5-HDAC4-HIF1α positive feedback loop. Oncogene 2023, 42(25):2047–2060.

Fang Y, Wu X, Gu Y, Shi R, Yu T, Pan Y, Zhang J, Jing X, Ma P, Shu Y: LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m(6) A-YTHDF2-dependent manner. Clinical and Translational Medicine 2023, 13(3):e1205.

Wang S, Wang Y, Zhang Z, Zhu C, Wang C, Yu F, Zhao E: Long Non-Coding RNA NRON promotes Tumor Proliferation by regulating ALKBH5 and Nanog in Gastric Cancer. Journal of Cancer 2021, 12(22):6861–6872.

Zhang J, Guo S, Piao HY, Wang Y, Wu Y, Meng XY, Yang D, Zheng ZC, Zhao Y: ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1. Journal Of Physiology And Biochemistry 2019, 75(3):379–389.

Hu Y, Gong C, Li Z, Liu J, Chen Y, Huang Y, Luo Q, Wang S, Hou Y, Yang S et al: Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification. Molecular Cancer 2022, 21(1):34.

Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC: Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology 2022, 33(10):992–1004.

Xiao D, Fang TX, Lei Y, Xiao SJ, Xia JW, Lin TY, Li YL, Zhai JX, Li XY, Huang SH et al: m(6)A demethylase ALKBH5 suppression contributes to esophageal squamous cell carcinoma progression. Aging 2021, 13(17):21497–21512.